Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Eritromax vs Eprex in Healthy Subjects
NCT03572647Phase 1Completed
- Sponsor
- Azidus Laboratories Limited
- Start
- Nov 2012
- Primary completion
- Nov 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised trial of Eritromax in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoints: Pharmacokinetic - rHuEPO concentration at 120 hours and Pharmacodynamics - Absolute Reticulocyte Count at 576 hours. Started Nov 2012; status: completed.
02
Drugs
Eritromax
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03572647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572647.